Loading...
XNASDYAI
Market cap47mUSD
Dec 24, Last price  
1.62USD
1D
-9.50%
1Q
43.36%
Jan 2017
-2.41%
Name

Dyadic International Inc

Chart & Performance

D1W1MN
XNAS:DYAI chart
P/E
—
P/S
16.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
17.48%
Revenues
3m
-1.07%
211,27216,740,84715,882,96915,383,75415,601,72017,134,74112,523,398315,712592,886758,4201,295,4511,681,0761,601,9212,403,8312,930,3032,898,806
Net income
-7m
L-27.48%
-190,781-6,079,582-10,514,570-10,882,1921,349,497-428,050-5,980,08965,787,318-3,608,739-2,135,819-5,691,756-8,307,965-9,325,273-12,921,654-9,370,884-6,795,461
CFO
-7m
L-16.79%
-128,489-5,916,889-7,815,092790,509365,1725,095,854-6,200,067-802,674-6,035,390-2,606,258-4,407,189-5,782,892-6,574,392-11,276,945-8,083,775-6,726,755
Earnings
Mar 26, 2025

Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
URL
https://dyadic.com/
IPO date
Nov 05, 2004
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,899
-1.07%
2,930
21.90%
2,404
50.06%
Cost of revenue
11,090
13,046
17,034
Unusual Expense (Income)
NOPBT
(8,191)
(10,116)
(14,631)
NOPBT Margin
Operating Taxes
(364)
(149)
Tax Rate
NOPAT
(8,191)
(9,751)
(14,482)
Net income
(6,795)
-27.48%
(9,371)
-27.48%
(12,922)
38.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
544
1,230
BB yield
-1.56%
-0.98%
Debt
Debt current
96
Long-term debt
226
Deferred revenue
176
353
Other long-term liabilities
Net debt
(6,941)
(12,926)
(20,545)
Cash flow
Cash from operating activities
(6,727)
(8,084)
(11,277)
CAPEX
Cash from investing activities
7,450
(2,369)
5,222
Cash from financing activities
544
1,230
FCF
(8,333)
(9,751)
(14,482)
Balance
Cash
7,263
12,642
20,260
Long term investments
285
285
Excess cash
7,118
12,780
20,425
Stockholders' equity
(80,236)
(73,441)
(63,706)
Invested Capital
86,300
84,705
82,450
ROIC
ROCE
EV
Common stock shares outstanding
28,799
28,364
27,838
Price
1.61
30.89%
1.23
-72.79%
4.52
-15.99%
Market cap
46,366
32.90%
34,888
-72.27%
125,828
-14.86%
EV
39,425
21,962
105,283
EBITDA
(8,191)
(10,082)
(14,301)
EV/EBITDA
Interest
381
Interest/NOPBT